During the COVID-19 pandemic, H1N1 seasonality disappeared worldwide. In Brazil, information on how coronavirus impacted this seasonality is scarce. In this study, we aimed to verify whether COVID-19 pandemic was associated with changes in the seasonality of H1N1, modeling the time series of H1N1 between pre-pandemic (2018 and 2019), pandemic (2020 and 2021) and post-pandemic (2022 and 2023) periods. For this purpose, we superimposed on this time series cases of COVID-19 from 2020 to 2023. Our findings highlighted that H1N1 exhibited a consistent seasonal pattern in the pre-pandemic period, with peaks mainly in months with the highest rainfall. However, this seasonality disappeared during the pandemic, with a significant decrease in the number of cases, in contrast with the predicted seasonality of H1N1 for the same period. In addition, the seasonal pattern of H1N1 in the post-pandemic showed a return to that observed in the pre-pandemic period, especially in 2023. We observed that the COVID-19 pandemic was consistently associated with changes in H1N1 seasonality in Brazil, underscoring the relative importance of monitoring patterns of respiratory syndromes to enhance our understanding of how coronavirus is associated with changes in seasonal diseases.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1590/0001-3765202420230645 | DOI Listing |
Am J Trop Med Hyg
January 2025
Department of Intensive Care, Amsterdam University Medical Center, Amsterdam, The Netherlands.
Epidemiology, ventilator management, and outcomes in patients with acute respiratory distress syndrome (ARDS) because of coronavirus disease 2019 (COVID-19) have been described extensively but have never been compared between countries. We performed an individual patient data analysis of four observational studies to compare epidemiology, ventilator management, and outcomes. We used propensity score weighting to control for confounding factors.
View Article and Find Full Text PDFPediatr Infect Dis J
January 2025
From the Department of Pediatrics, Niigata University, Graduate School of Medical and Dental Sciences, Niigata, Japan.
Background: The spread of the BA.5 Omicron variant of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has increased the number of hospitalized children. However, the impact of the spread of new omicron subvariants in children remains poorly described.
View Article and Find Full Text PDFRetina
January 2025
Tennessee Retina, Nashville, TN.
Purpose: To describe the patterns of ocular inflammation following COVID-19 vaccination, assess underlying commonalities and understand outcomes.
Methods: Retrospective, multicenter cohort study, conducted between 2020 and 2021. Patients with no previous uveitis history (de novo) or a known uveitis history (recurrent) who developed ocular inflammation within 42 days of COVID-19 vaccination were identified.
Psychol Health Med
January 2025
Department of Specialised Nursing, Faculty of Health Sciences, Jagiellonian University - Medical College, Cracow, Poland.
Pandemic COronaVIrus Disease-19 (COVID-19) was a traumatic event that had a significant impact on the mental health of healthcare workers (HCWs), especially intensive care units (ICUs). Months of exposure and the threat of death can lead to post-traumatic stress disorder (PTSD), and high physical and emotional strain can lead to burnout syndrome (BOS). The purpose of this study was to assess the prevalence of PTSD and BOS among ICU HCWs during the COVID-19 pandemic.
View Article and Find Full Text PDFRev Inst Med Trop Sao Paulo
January 2025
Universidade de São Paulo, Faculdade de Medicina, Hospital das Clínicas, Divisão de Clínica de Moléstias Infecciosas e Parasitárias, Laboratório de Investigação Médica em Imunologia (LIM-48), SSão Paulo, São Paulo, Brazil.
Immunocompromised individuals were considered high-risk for severe disease due to SARS COV-2 infection. This study aimed to describe the safety of two doses of COVID-19 adsorbed inactivated vaccine (CoronaVac; Sinovac/Butantan), followed by additional doses of mRNA BNT162b2 (Pfizer/BioNTech) in immunocompromised (IC) adults, compared to immunocompetent/healthy (H) individuals. This phase 4, multicenter, open label study included solid organ transplant and hematopoietic stem cell transplant recipients, cancer patients and people with inborn errors of immunity with defects in antibody production, rheumatic, end-stage chronic kidney or liver disease, who were enrolled in the IC group.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!